Entest Group, Inc. Stock Price - ETNI

Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
VAT not included
Company Name Stock Ticker Symbol Market Type
Entest Group, Inc. (PC) ETNI OTCMarkets Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 0.018948 0.00 0.00 0.00 0.018948 08:00:05
Bid Price Ask Price Spread Spread % News
0.0126 0.0195 0.0069 35.38% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Entest Group, Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 931.69k 49.17M $ -1.48M - - 17.04M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
27.82k $ - 0.00% - -

more financials information »

Entest Group, Inc. News

Loading Messages....

Latest ETNI Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ETNI Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.0230.0230.01450.019140539,409-0.00405-17.62%
1 Month0.015970.0230.01430.018886915,4630.0029818.65%
3 Months0.020.0230.01230.018592115,497-0.00105-5.26%
6 Months0.01550.0230.01160.016790215,2320.0034522.25%
1 Year0.01550.030.00360.014782630,1920.0034522.25%
3 Years0.0210750.08890.00360.035497557,548-0.00213-10.09%
5 Years0.00010.09190.00010.00133581,519,6250.0188518,848.0%

Entest Group, Inc. Description

Entest BioMedical, Inc. is a biotechnology company dedicated to developing treatments that harness the body's own reparative/immunological mechanisms. The Company is currently developing Immuno-Therapeutic Cancer Vaccines for dogs. The Company sees applications for its areas of focus in beyond animal venues to human applications. The Company has adopted a veterinary first approach, believing once efficacy in animals is established and near term revenue achieved, viability in transitioning to human applications can be made via joint ventures and license agreements.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.